Cost-effectiveness of FDA-approved anti-VEGF treatments, ranibizumab and aflibercept, for diabetic macular edema from a US perspective: analysis of 2-Year Protocol T comparative effectiveness results

Duff Steve; Holekamp Nancy; Rajput Yamina

首页> 外文期刊>Investigative ophthalmology & visual science >Cost-effectiveness of FDA-approved anti-VEGF treatments, ranibizumab and aflibercept, for diabetic macular edema from a US perspective: analysis of 2-Year Protocol T comparative effectiveness results

【24h】

Cost-effectiveness of FDA-approved anti-VEGF treatments, ranibizumab and aflibercept, for diabetic macular edema from a US perspective: analysis of 2-Year Protocol T comparative effectiveness results

机译：FDA批准的抗VEGF治疗，Ranibizumab和AfliBercept的成本效益，用于来自美国的糖尿病性黄斑水肿：分析2年议定书T比较效果结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Investigative ophthalmology & visual science》 |2017年第8期|共2页
作者
Duff Steve; Holekamp Nancy; Rajput Yamina;
展开▼
作者单位

Veritas Hlth Econ Consulting Inc Carlsbad CA USA;

Pepose Vis Inst Chesterfield MO USA;

Genentech Inc San Francisco CA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类眼科学;
关键词

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness of FDA-approved anti-VEGF treatments, ranibizumab and aflibercept, for diabetic macular edema from a US perspective: analysis of 2-Year Protocol T comparative effectiveness results [J] . Duff Steve, Holekamp Nancy, Rajput Yamina Investigative ophthalmology & visual science . 2017,第8期

机译：FDA批准的抗VEGF治疗，Ranibizumab和AfliBercept的成本效益，用于来自美国的糖尿病性黄斑水肿：分析2年议定书T比较效果结果
2. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial [J] . Ross Eric L., Hutton David W., Stein Joshua D., JAMA ophthalmology . 2016,第8期

机译：从糖尿病性视网膜病变临床研究网络比较有效性试验中，Aflibercept，Bevacizumab和Ranibizumab用于糖尿病性黄斑水肿治疗的成本效益分析
3. Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective [J] . Stephane A Régnier, William Malcolm, Jennifer Haig, ClinicoEconomics and Outcomes Research . 2015,第2期

机译：雷尼单抗与阿柏西普治疗糖尿病性黄斑水肿所致视力障碍的成本效益：英国医疗保健观点
4. Morphology of vascular network in eyes with diabetic macular edema varies based on tolerance of aflibercept treatment interval length: preliminary findings [C] . Prateek Prasanna, Justis Ehlers, Nathaniel Braman, Biomedical Applications in Molecular, Structural, and Functional Imaging . 2019

机译：患有糖尿病黄斑水肿的眼睛中血管网络的形态基于AfliBercept治疗间隔长度的耐受性因耐受性而变化：初步调查结果
5. Prediction of visual acuity loss and indications for laser treatment in patients with diabetic macular edema using the Heidelberg Retina Tomograph. [D] . O'Neal, Dennis A. 2007

机译：使用海德堡视网膜断层扫描仪预测糖尿病性黄斑水肿患者的视力下降和激光治疗的适应症。
6. Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective [O] . Stephane A Régnier, William Malcolm, Jennifer Haig, 2015

机译：雷尼单抗与阿柏西普治疗糖尿病性黄斑水肿所致视力障碍的成本效益：英国医疗保健观点
7. PSS25 - COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT VERSUS RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR EDEMA (DME) UNDER THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS) [O] . M.P. Rosim, B.S. Riveros, H.S. Kim, 2018

机译：PSS25 - 术治疗巴西公共医疗保健系统（SUS）治疗术治疗糖尿病黄斑水肿（DME）的术治疗术治疗糖尿病黄斑水肿（DME）的成本效益分析

Cost-effectiveness of FDA-approved anti-VEGF treatments, ranibizumab and aflibercept, for diabetic macular edema from a US perspective: analysis of 2-Year Protocol T comparative effectiveness results

著录项

相似文献

相关主题

期刊订阅